A study aimed at understanding the MYCN-triggered epigenetic reprogramming of prostate cancer to neuroendocrine prostate fate, the cistrome, and the transcriptome of these tumours were investigated in vitro, in vivo, and in patient-derived organoids. The gene discussed is MYCN; the disease is prostate carcinoma.